Shalby Sees Short-Term International EBITDA Breakthrough, FY27 Capex Cooled

Shalby Limited — Q4 FY2026 Earnings Call (May 29, 2026)

1. Overall Tone of Management: Optimistic

• Management highlighted “healthy improvement” and “strong growth” across revenue and profitability.
• Repeated confidence language: “we are confident,” “very confident,” “expecting a significant upside,” and “positioned at an important inflection point” (MedTech).

2. Key Themes from Management Commentary

• Group profitability rebound (hospital + tax regime impact):
• Q4 PAT swung to profit; CFO attributed improvement partly to “change in our tax regime” as a “recurring benefit.”
• Hospital business: stabilization after prior turbulence
• Doctor attrition/insurance turbulence referenced as having been “addressed properly.”
• Occupancy expected to improve; occupancy guidance given qualitatively as “north of 50%” next year.
• Closure of two SOCEs (Rajkot, Lucknow) cited as a reason for lower occupied beds/occupancy.
• International hospital (Gurugram/PK Healthcare): profitability path
• International patients impacted by “U.S. and Iran conflict,” but management claims “healthy profitability margin” and “strong comeback” in April–May.
• NABH accreditation received in Feb; management expects it to drive “upside on revenue” and EBITDA breakeven “in the short term” (timeline not provided).
• Shalby MedTech: transition to scale/execute
• Narrative: “build and invest phase to a scale and execute phase.”
• Reported MedTech turnaround: Q4 EBITDA positive for “second consecutive quarter.”
• Focus areas: COGS optimization, inventory productivity, multi-vendor sourcing (“China Plus One”), and scaling global market access.
• Capex and investment intensity
• FY26 capex ~INR160 crores; emphasis on oncology/radiation bunkers and robotics.
• FY27 capex described as not “large spending” after heavy FY26 investment.
• Strategic pivot away from aggressive franchise model
• Franchisees continue but “may not be able to do it as aggressively” as earlier planned; “very picky.”

3. Q&A Analysis

Theme A: International hospital profitability & timeline (Gurugram/PK Healthcare)

• Core questions
• When will Shalby International reach EBITDA breakeven?
• What is the profitability of international business (including U.S. vs other geographies)?
• Management response
• International hospital: timeline not given due to restriction, but “very confident to see this happening in the short term only.”
• Drivers cited: NABH accreditation (received Feb), TPA renewals, Africa/CIS growth, and cost optimization.
• U.S./implant profitability: MedTech implant business has “second consecutive quarter of positive EBITDA,” but still “some distance” to double-digit EBITDA and positive cash flow.
• Conflict impact: U.S. and Iran conflict impacted international patients in Q4, but management claims offset via Africa/CIS and “strong comeback” in April–May.
• Evasive/partial elements
• No specific date for EBITDA breakeven (“cannot comment on the timeline”).
• “Short term” repeated without quantification.

Theme B: Debt/borrowings rationale and trajectory

• Core questions
• Why borrowings/debt are rising; where debt is used.
• Management response
• Debt largely linked to two acquisitions (U.S. and Gurugram).
• After MedTech international breakeven, incremental debt “would not be that significant.”
• Debt-to-equity described as “healthy” and improving trends expected.
• Notable
• No explicit FY27/FY28 debt numbers provided in this call.

Theme C: FY27 outlook: margins, tax rate, capex, and guidance

• Core questions
• Expected tax rate for FY27.
• Capex in FY26 and target for FY27.
• Any guidance for FY27 (revenue/EBITDA/margins).
• Management response
• Tax: moved to new regime; FY27 tax “lower tax of 25%” vs 35% earlier; described as recurring benefit.
• Capex: FY26 capex “approx. INR160 crores” (LINAC bunkers, robotics).
• FY27: management says heavy FY26 capex already done; “do not see a large spending coming into FY ’27.”
• Guidance: qualitative “significant upside into revenue and EBITDA,” but no quantitative consolidated targets.
• Evasive/partial elements
• Asked for FY27/FY28 consolidated EBITDA margin and debt levels—management refused to comment on numbers (“restricted to comment on the numbers”).

Theme D: Operational metrics: occupancy, beds, gross margin decline

• Core questions
• Why operational beds/occupancy down YoY?
• Why gross margin decreased (90% → 85%)?
• What occupancy to expect next year?
• Management response
• Beds/occupancy down due to closure of Rajkot and Lucknow SOCEs; those were EBITDA negative.
• Gross margin: attributed to new doctor recruitment (timing lag) and oncology expensive medicines; management exploring measures to protect gross margin.
• Occupancy: expects “north of 50%” next year; confidence driven by improvements in units like Gurugram, Indore, Surat.
• Notable
• Gross margin explanation partially overlaps with EBITDA/doctor cost timing; management acknowledged gross margin impact from oncology medicines.

Theme E: Franchise model & expansion plan

• Core questions
• Franchisee plan: earlier target of 50 franchisees—still valid?
• Expansion plan for next ~2 years; expected EBITDA hit from expansion.
• Management response
• Franchisees: continue but “not as aggressively”; “very picky.”
• Expansion: selective bed additions only where profitable and quality standards met; also MedTech expansion into countries like Myanmar and Vietnam (approvals expected “very shortly”).
• EBITDA hit: no quantified “hit”; expansion described as selective with focus on profitability/cash flows.

4. Guidance / Outlook

Explicit guidance (quantitative)

• Occupancy (qualitative-to-quantitative): “north of 50%” occupancy in the coming year (asked directly; answered “Yes, it is likely.”).
• Tax rate: FY27 tax rate “25%” (vs 35% earlier).
• Capex: FY26 capex “approx. INR160 crores”; FY27 described as not large spending (no number).

Implicit signals (qualitative)

• Hospital: “significant upside” in revenue/EBITDA; doctor stability improving; Q2 onwards indicators expected (“Q2 onwards, it would be there”).
• International hospital: EBITDA breakeven expected “in the short term only” (no date).
• MedTech: positioned at “important inflection point” with focus on scaling revenues, improving profitability, and global penetration.
• Debt: incremental borrowing not expected to be significant post breakeven; debt-to-equity improving trend.

5. Standout Statements (direct quotes where useful)

• Tax regime as recurring profitability driver:
• “change in our tax regime… reflecting a recurring benefit to our profitability in the coming subsequent years.”
• International hospital confidence without timeline:
• “cannot comment on the timeline” but “very confident to see this happening in the short term only.”
• Conflict impact + rebound claim:
• Q4 impacted by “U.S. and Iran conflict,” but “strong comeback… in April and May.”
• MedTech turnaround durability:
• “second consecutive quarter of positive EBITDA performance.”
• MedTech scaling narrative:
• “transition from build and invest phase to a scale and execute phase.”
• Gross margin decline explanation:
• Gross margin down due to “expensive medicines” on oncology growth and doctor ramp timing.
• Franchise strategy shift:
• “may not be able to do it as aggressively as we had planned earlier… very picky.”

6. Red Flags / Positive Signals

Red flags
– No quantitative FY27 margin/debt guidance despite direct questions (management repeatedly says restricted to comment on numbers).
– Profitability improvement partly attributed to tax regime change—could be less “operationally sustainable” than margin-driven growth.
– International hospital breakeven timeline avoided (“cannot comment on timeline”).
– Geopolitical uncertainty acknowledged (U.S./Iran conflict) with reliance on offsetting markets—could be volatile.

Positive signals
– Clear operational improvements: Q4 group EBITDA margin up (12.7% vs 9.7% YoY).
– MedTech shows sustained EBITDA positivity (two consecutive quarters).
– Management provides specific operational drivers (NABH, TPA renewals, cost optimization, inventory turns, China Plus One).
– Occupancy target anchored: “north of 50%.”

7. Historical Comparison & Consistency Analysis (vs prior calls)

a. Change in Tone Over Time

• Current (Q4 FY26): More Optimistic
• Stronger confidence and “inflection point” language for MedTech.
• Hospital narrative shifts from “turbulence/one-off” (Q3) to “addressed properly” and “upside.”
• What changed
• Q3 emphasized stabilization and “positivity in the current quarter” with several moving parts (insurance stoppage, doctor losses, approvals timing).
• Q4 adds harder financial outcomes (PAT swing, EBITDA margin expansion) and recurring tax benefit framing.

b. Tracking Past Commitments vs Outcomes

• Franchise expansion aggressiveness
• Past (Q3 FY26): franchise model discussed; later in Q4 management says franchisees “may not be able to do it as aggressively” and no specific number.
• Outcome: ⏳ Delayed / scaled back (plan not reaffirmed with targets).
• International hospital EBITDA breakeven timing
• Past (Q3 FY26): management said it was “likely to be EBITDA positive… about 2 quarters ago” but delayed due to management issues; NABH expected “very soon.”
• Current (Q4 FY26): NABH received Feb; still “cannot comment on timeline,” but “very confident… in the short term.”
• Outcome: ⏳ Delayed (breakeven not yet concretely achieved; timeline still not provided).
• Doctor/insurance turbulence resolution
• Past (Q3 FY26): insurance work stopped for 2–2.5 months; contracts signed again end-Nov; expected flow improvement.
• Current (Q4 FY26): doctor attrition “addressed properly”; occupancy and profitability improved.
• Outcome: ✅ Partially delivered (Q4 shows improved margins and profitability; occupancy still not at target but guided upward).

c. Narrative Shifts

• From “one-off/turbulence” to “recurring structural benefit”:
• Q3: more operational explanations (insurance negotiations, doctor churn, approvals).
• Q4: adds tax regime change as a recurring profitability driver.
• Franchise strategy de-emphasized:
• Q3 discussed franchisees and expansion capacity; Q4 explicitly tempers aggressiveness and focuses on core hospitals + implant business.
• International risk framing evolves:
• Q3: NABH/clinical talent as key.
• Q4: adds geopolitical conflict as a direct driver of international patient revenue volatility, with offset via Africa/CIS.

d. Consistency & Credibility Signals

• Medium credibility
• Management provides plausible operational drivers, but:
  • Timelines are repeatedly softened (international hospital breakeven).
  • Guidance remains qualitative even when asked for quantitative FY27/FY28 EBITDA margin and debt levels.
• However, the call does show material financial improvement in Q4, supporting credibility on execution vs prior quarters.

e. Evolution of Key Themes

• Hospital margins/occupancy: Improving trajectory but still dependent on unit-level stabilization (Gurugram, Indore, Surat).
• MedTech: Clear inflection narrative strengthened; turnaround now evidenced by consecutive positive EBITDA.
• Geopolitics: Not a central theme in Q3; becomes explicit in Q4 as a revenue headwind.
• Capital allocation: FY26 heavy capex; FY27 described as lighter—consistent with “invest then scale” story.

f. Additional Insights (cross-period intelligence)

• The company’s profitability improvement appears to be multi-factor:
• operational turnaround (especially MedTech),
• hospital stabilization,
• and tax regime change (potentially non-operational).
• International hospital breakeven remains a key unresolved milestone: even after NABH receipt, management still avoids a timeline—suggesting either ramp is slower than expected or profitability is still sensitive to patient mix/TPA renewals and geopolitical effects.